Ocugen has tested support twice at the $7.80-$8.00 range. There was a sharp sell-off after WHO approval was announced, but it's likely that approval added $1-$2 to the consolidating price. Two important catalysts are on the horizon: Potential Canadian approval and USA pediatric EUA. Ocugen will resume a strong uptrend if either of these comes through. Historically, Ocugen likes to dip to oversold territory before the strong pump. This is already happening now.
Ocugen's small supply and heavy short interest make it a good candidate for a parabolic run. If you can handle the volatility, I wouldn't sleep on this stock.